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ABSTRACT
FAIRMAN, C. M., T. S. NILSEN, R. U. NEWTON, D. R. TAAFFE, N. SPRY, D. JOSEPH, S. K. CHAMBERS, Z. P. ROBINSON, N. H.
HART, M. C. ZOURDOS, B. C. FOCHT, C. J. PEDDLE-MCINTYRE, and D. A. GALVÃO. Reporting of Resistance Training Dose, Ad-
herence, and Tolerance in Exercise Oncology.Med. Sci. Sports Exerc., Vol. 52, No. 2, pp. 315–322, 2020.Purpose:While general guidelines (such
asCONSORTorConsensus on Exercise Reporting Template) exist to enhance the reporting of exercise interventions in the field of exercise science,
there is inadequate detail facilitating the standardized reporting of resistance training adherence in the oncology setting. The purpose of this studywas
to apply a novel method to report resistance training dose, adherence, and tolerance in patients with cancer.Methods:A total of 47 prostate cancer
patients (70.1 ± 8.9 yr, bodymass index, 28.6 ± 4.0) with bonemetastatic disease completed an exercise program for 12wk.We assessed traditional
metrics of adherence (attendance and loss to follow-up), in addition to novel proposed metrics (exercise-relative dose intensity, dose modification,
and exercise interruption). Total training volume in kilograms (repetitions sets training load (weight)) was calculated for each patient.Results:
Attendance assessed from traditional metrics was 79.5% ± 17.0% and four patients (9%) were lost to follow-up. The prescribed and actual cumu-
lative total dose of resistance training was 139,886 ± 69,150 kg and 112,835 ± 83,499 kg, respectively, with a mean exercise-relative dose intensity
of 77.4%± 16.6% (range: 19.4% –99.4%). Resistance trainingwasmissed (1–2 consecutive sessions) or interrupted (missed ≥3 consecutive sessions)
in 41 (87%) and 24 (51%) participants, respectively. Training dose was modified (reduction in sets, repetitions, or weight) in 40 (85%) of patients.
Importantly, using attendance as a traditional metric of adherence, these sessions would have all counted as adherence to the protocol.Conclusions:
Traditional reporting metrics of resistance training in exercise oncology may overestimate exercise adherence. Our proposed metrics to capture re-
sistance training dose, adherence, and tolerance may have important applications for future studies and clinical practice. Key Words:
EXERCISE-RELATIVE DOSE INTENSITY, EXERCISE INTERRUPTION, DOSE MODIFICATION, WEIGHT TRAINING
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Asthe field of exercise oncology is rapidly expanding,exercise has been increasingly recognized as an impor-tant therapeutic intervention to combat several cancer-
and treatment-related adverse effects (1–5). There is a plethora
of evidence highlighting the benefits of resistance training (RT)
in this regard (2,4–9). Despite the promise of RT within exer-
cise oncology, recent literature has highlighted improving the
training prescription as central for progress in this area to con-
tinue (10). To improve prescription, it is important to examine
how training variables (i.e., volume, intensity, frequency, type,
and duration) and key principles (individualization, progressive
overload, and specificity) are used within the current literature,
but authors have often neglected to report these details (11,12).
Further, several systematic reviews have demonstrated the con-
sistent underreporting regarding the specifics of RT variables in
clinical interventions (13–16), which significantly limits the
applicability of findings and hinders the ability to progress in
the design of precise interventions. Further, RT variables should
be sequenced in a manner which aims to maximize specific
outcomes of interest (i.e., periodization) (12); however, this
is rarely the case in exercise oncology, possibly leading to a
lower magnitude of benefit.
Despite underwhelming reporting of specific training vari-
ables, several reporting guides for clinical exercise interventions
do exist, such as the CONSORT statement (17) and Consensus
on Exercise Reporting Template (CERT) (18). The CERT pro-
vides guidelines for reporting the dosage of prescribed exercise
using number of sets, repetitions, and duration (18). However,
authors usually provide a range rather than exact numbers of
these variables (i.e., three to five sets of 8–12 repetitions) mak-
ing it difficult to quantify metrics such as total volume load
(sets  repetitions  weight lifted) in which precise numbers
are needed. Further, “adherence” to a program is typically de-
fined as attendance (i.e., whether or not an individual shows
up to a session), which gives little insight into the actual dose
of exercise received by participants (i.e., number, type, and
reasons for deviations from the prescribed dose). In fact, the
“actual dose”more accurately reflects the adherence to a protocol
as the extent to which an individual adheres to the prescribed
program (set, repetitions, load, etc.).Without these details, partic-
ularly the dose of exercise that was actually achieved rather than
prescribed, results could lead to over reporting of actual dose of
RT completed. Therefore, current reporting standards may be in-
sufficient to capture the necessary detail and true nuances of RT
prescription. Recently, Nilsen et al. (19) presented a novel
method for reporting exercise dose and adherence specific to aer-
obic training. The purpose of this study was to investigate the re-
ported dose, adherence, and tolerance of RT from a recent trial in
individuals with advanced prostate cancer.
METHODS
Participants
This is a follow-up analysis using data from a prior two-
arm, randomized controlled trial to assess the effect of exercise
compared with usual care in individuals with advanced prostate
cancer. Details of inclusion criteria and recruitment have been
previously reported (20). After study completion and posttest
assessment, the usual care group was invited to perform the
same exercise program prescription and assessments. Data con-
tributed by these additional patients were pooled to extend the
number of assessable patients with data on RT. The flow of par-
ticipants through the study can be found in Figure 1. The study
was approved by the University Human Research Ethics Com-
mittee, and all patients provided written informed consent.
Exercise Program
The RT component of this program has been previously de-
scribed in detail (20,21). Briefly, six resistance exercises that
targeted the major upper- and lower-body muscle groups and
were part of modular multi-modal exercise program were per-
formed thrice weekly for 12 wk and supervised by an exercise
physiologist. The exercise selection was modified based on
the location and extent of bone metastases to avoid loading
skeletal bone lesions as previously described and used in prior
research in this population (20). Specifically, the core exer-
cises included leg press, leg extension, leg curl, chest press,
seated row, and triceps pulldown. Exercise modifications or
substitutions were required based on the location and extent
of metastases. Modifications included substituting an exercise
with another that did not load the specific site (for example, leg
press was avoided for individuals with bone metastases in the
pelvic region), or unilateral limb loading of the region unaf-
fected by bone metastases (if metastases were present in left
femur, individuals were encouraged to perform unilateral knee
extension/flexion with right limb). In the instance of extensive
metastases, this resulted in avoidance of multiple exercises.
For more information on the modular aspects of the exercise
prescription, readers are directed to previous publications de-
tailing this approach (20,21).
The RT program was designed to progress from lighter resis-
tance and more repetitions to heavier resistance and fewer repeti-
tions using 12 to 8 repetitions for two to four sets per exercise
(Table 1). Load (kg) was increased using 5% to 10% increments
for the next set or training session if the patient was able to perform
more repetitions than the repetition maximum (RM) specified dur-
ing a given set. Any modification to the exercise prescription (ex-
ercise selection, altering sets, and/or repetitions) was undertaken at
the discretion of the supervising exercise physiologist.
Volume metrics. Prescribed training volume and com-
pleted training volume (sets repetitions load) was calculated
for each individual exercise, summed to provide a total session
volume. Further, total volume from all sessions was summed
to derive both the total prescribed and actual cumulative volume
per patient. Exercise-relative dose intensity (ExRDI) was also
calculated and was defined as the ratio of total actual to total pre-
scribed cumulative dose, expressed as a percentage. An ExRDI
of 100% indicates that a patient was able to perform the RT pre-
scription, without dose modification, whereas an ExRDI of 70%
would indicate that a patient required some sort of dose modifi-
cation (reduction in sets, repetitions or weight) by 30% of the
prescribed dose.
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Dose modification quantification. Attendance was
quantified as a percentage of how many total sessions a partic-
ipant attended, regardless of how much training was com-
pleted during the session. We defined adherence outcomes
as proposed in previous research (19):missing session defined
as missing single or two consecutive sessions; exercise inter-
ruption defined as missing three or more consecutive exercise
sessions; and permanent exercise discontinuation defined as
the permanent discontinuation of exercise before week 12.
Further, loss to follow-up (i.e., participants with baseline data
but no data for postintervention assessment) was also re-
corded. Session dose modification was defined as any session
requiring the prescribed dose (number of set and/or repeti-
tions and/or training load reduced) to be modified during the
session. Dose escalation was defined as any session where
dose was modified to progress individuals (i.e., load was
higher than initially prescribed.
Metrics are presented as the number and percentage of pa-
tients requiring at least one of the above-presented criteria,
and number and percentage of sessions that met the above
described criteria. This information was also collated to gar-
ner information on adherence per session, per patient, and
per exercise.
Statistical Analysis
Descriptive statistics (mean ± SD and frequencies) were
used for baseline characteristics. Dose and tolerability vari-
ables for RT were summarized by mean (SD and range, where
appropriate), including all patients who initiated the exercise
intervention program. A paired sample t test was used to deter-
mine the difference between planned and actual cumulative RT
dose. Descriptive statistics were calculated using Microsoft Ex-
cel (2016) with other analyses conducted using SPSS (version
22.0, IBM, Chicago, IL).
RESULTS
Patient characteristics are presented in Table 2. Patients were
age 70.15 ± 8.90 yr and presented with extensive metastatic
FIGURE 1—CONSORT diagram.
TABLE 1. Resistance exercise prescription.
Weeks Session Sets Repetitions
1–2 1–6 2 12
3–4 7–12 3 12
5–6 13–18 3 10
7–9 19–27 4 10
10–12 28–36 4 8
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lesions in the pelvis (77.3%), femur (36.4%), rib/thoracic ver-
tebrae (61.4%), lumbar vertebrae (38.6%), humerus (18.2%),
and other sites (65.9%). Ninety-three percent of patients were
undertaking androgen deprivation therapy.
Conventional Attendance Metrics
Using conventional metrics, training session attendance
was 79.5% (range, 19.4%–100%) Four participants were lost
to follow-up due to increased bone pain (n = 2), health deteri-
oration (n = 1), or a fall at home (n = 1).
Exercise Dose Quantification and
Adherence Metrics
The prescribed total cumulative exercise dose across the inter-
vention was 139,886 ± 69,150 kg (range, 7872–300,546 kg)
(Fig. 2A), which yielded a mean weekly training volume of
3886 ± 37 kg (range: 2062–4848 kg). The completed cumu-
lative total exercise dose across the intervention was
112,835 ± 83,499 kg (range: 7104–240,788 kg) (Fig. 2A).
There was a statistically significant difference between the
prescribed and completed cumulative dose (P = <0.001).
The prescribed and completed training volume per session
is depicted in Figure 2B. The ExRDI was 77.4% ± 16.6%
(range: 19.3%–99.4%) (Fig. 2C), indicating that the dose
was modified/interrupted for ~22.6% of the sessions.
The dose was interrupted in 24 (51%) of the participants
due to a variety of health-related (e.g., general illness, treat-
ment related pain, etc.) and non-health related (e.g., vacation)
reasons (Table 3). Forty-four patients (87%) missed one or
more exercise sessions during the intervention, with most
missed sessions due to conflicting appointments and general
illness. The dose was modified in 41 (87%) of patients and 149
(9%) of sessions. Specifically, dose was modified via the reduc-
tion in load (n = 79; 53%), reduction in sets (n = 19; 13%), rep-
etitions (n = 9; 6%), different exercise selection (n = 2; 1%) or
exercise removal (n = 38; 25%). Dose was modified for a vari-
ety of health-related (n = 94; 5%) and non-health-related rea-
sons (e.g., time-constraints, equipment availability, previously
missed session) (n = 55; 3%). On the other hand, dose escala-
tion occurred in 19 (40%) of the patients. Adjustments were un-
dertaken by exercise physiologists to ensure an appropriate load
was assigned, and the principle of progressive overload was
followed. Additionally, adherence per patient is presented in
Figure 3A, and adherence per exercise in Figure 3B.
DISCUSSION
This retrospective analysis was conducted to examine the
specific dosage of training that was completed in our previous
exercise oncology trial (20) to make recommendations going
forward on how to calculate more precise metrics for training
completion in clinical intervention studies and improve the ap-
plicability of study design and interpretation of the results.
There were three important findings of a RT intervention in
prostate cancer patients with bonemetastases: 1) the prescribed
total volume of RT was higher than the actual completed vol-
ume as reflected by an ExRDI of 77.4%; 2) RTwas interrupted
in half of the patients and missed (i.e., participants did not at-
tend for one or two consecutive sessions) in ~90% patients;
and 3) training dose throughout the intervention was modified
in ~85%of patients. Similar to the present findings, Nilsen et al.
conducted a retrospective analysis of a 24-wk aerobic training
program in prostate cancer patients undergoing ADT and re-
ported an ExRDI of ~77%, with training interrupted and/or
modified in 44% and 96% of patients, respectively. Addi-
tionally, Scott et al. (22) reported that aerobic training was
interrupted in 46% of patients, missed in 100% of patients
and modified in 49% of patients in a 36-session aerobic train-
ing trial in individuals with metastatic breast cancer. Overall,
the results of this retrospective analysis are in concert with
others and reveal the methods of exercise dose reporting
outlined by Nilsen et al. (19) for aerobic exercise can be ef-
fectively adapted for RT.
The purpose of performing this retrospective analysis on
this populationwas to provide an illustration of how these met-
rics can be applied to resistance exercise trials in individuals
with cancer. A novel aspect of adopting advanced adherence
metrics when reporting RT interventions is the ability to de-
termine the tolerability of different exercises in individuals
at different stages of disease, or different cancer populations.
Despite the modular aspect of this program, dose modifica-
tions during individual training sessions were still required
as a result of bone pain or upper-/lower-extremity pain and accu-
mulated fatigue. Thus, implementing this strategy and tracking
dose modification metrics may provide valuable information
concerning the tolerability of specific exercises where the fre-
quency and magnitude of dose modifications will likely vary
TABLE 2. Participant characteristics at baseline.
Variables Mean (SD)
Age (yr) 70.15 (8.90)
Height (cm) 174.51 (4.87)
Weight (kg) 86.87 (13.50)
Comorbidities
Hypertension, n (%) 21 (47)
Hypercholesteremia, n (%) 21 (47)
Cardiovascular disease, n (%) 11 (25)
Diabetes, n (%) 8 (18.2)
Osteoporosis, n (%) 0 (0)
Gleason score 8.05 (1.17)
PSA 34.7 (100.7)
Months since diagnosis 50.02 (56.91)
Months since metastases 10.70 (18.04)
Bone lesion site
Pelvis, n (%) 34 (77.3)
Femur, n (%) 16 (36.4)
Rib/thoracic vertebrae, n (%) 27 (61.4)
Lumbar vertebrae, n (%) 17 (38.6)
Humerus, n (%) 8 (18.2)
All regions, n (%) 3 (6.8)
Other site, n (%) 29 (65.9)
Treatment
Current ADT, n (%) 41 (93.2)
ADT months 5.3 (6.7)
Radiation, n (%) 22 (50)
Radiation for bone, n (%) 7 (15.9)
Brachytherapy, n (%) 5 (11.4)
Chemotherapy, n (%) 8 (18.2)
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across the cancer spectrum and intervention time course, as
will the reasons for these interruptions/modifications (22).
For example, having to substitute or modify upper body RT
exercises (i.e., incorporating physical therapy exercises for
postsurgery, rather than traditional RT exercises) in women
with breast cancer as a result of treatment-related dysfunction
could potentially explain reasons why limited or no improve-
ments were seen in upper body strength (23). Another example
could be individuals with head and neck cancer undergoing
chemotherapy and/or radiotherapy who need consistent dose
reductions as a result of low energy from malnutrition or other
acute treatment toxicities (24).
This process of dose modification essentially refers to the
concept of autoregulation, where the training stimulus is modi-
fied in accordance with an individual’s “readiness to train.” In
this sense, subjective/objective measure of sleep, fatigue, en-
ergy, recovery (or other relevant indices) can be used to provide
an individualized, appropriate training stimulus (12,23).
Further, it has been posited that the flexibility of autoregula-
tion within a periodized program may help ward off staleness,
improve enjoyment, and ultimately foster the long-term main-
tenance of activity (12). Irrespective, reporting dose modifica-
tions via exercise selection in these circumstances can lend
further insight into the feasibility of delivering an exercise in-
tervention during periods of illness, dysfunction, or transient
toxicity, which provides important information for practitioners
to understand the expectations and challenges of working with
specific populations.
Implementing traditional metrics, outlined by Nilsen et al.
(19), of adherence in exercise trials, such as loss to follow-
up and session attendance alone, have limited utility because
theymay lack breadth and specificity that is critical to defining
adherence and tolerance of the RT dose prescribed in the inter-
vention. For example, Scott et al. (22) reported that some type
FIGURE 2—Data are mean ± SD. Prescribed vs actual cumulative training volume (A) and mean training volume per session (B) (Green colored bars
indicate prescribed dose, whereas red colored bars indicate actual or completed dose.); ExRDI per session across the intervention (C).
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of dose modification and early session termination occurred in
49% and 36% of all training sessions, respectively in their trial;
however, conventional metrics would have classified the mod-
ified and terminated sessions as 100% adherence. Clearly, this
traditional metric limitation highlights the need to calculate ad-
herence in a more precise manner. Specifically, if sessions in
which dose modification occurs are counted as 100% atten-
dance then this does not provide an accurate picture of the par-
ticipant’s feasibility and tolerability of exercise, particularly in
advanced cancers or periods of intense cancer treatments,
highlighted by almost half of the sessions in the study by Scott
et al. (22) being modified in some way. Consequently, adapta-
tions may be compromised when exercise dosage is decreased.
For example, Scott et al. (22) had a predetermined feasibility
threshold set at an ExRDI of 70%, the authors reported that in-
dividuals who did not meet this threshold experienced an 11%
decline in peak oxygen consumption whereas those with an
acceptable feasibility (ExRDI ≥ 70%) experienced a significant
improvement in cardiorespiratory fitness (22). Ultimately, it
seems clear that altering a training session dose can affect study
outcomes, and this should be considered when examining the
feasibility of exercise interventions in various cancer popula-
tions, and should impact training recommendations in practice.
Importantly, simply using ExRDI (and other metrics) only
addresses reporting and not the quality of an intervention.
The CONSORT and CERT statements provide excellent
frameworks for the reporting of randomized controlled trial
components. However, the specifics of these guidelines are
open to interpretation and can be limited when it comes to cap-
turing the complexity of RT dose received, as noted by several
systematic reviews, which demonstrated that RT intervention
characteristics remain consistently underreported (13–16).
Thus, the methods of reporting adherence outlined in this arti-
cle should be utilized in parallel with the reporting guidelines
outlined by CONSORT or CERT (18). Ultimately, the appli-
cability of exercise is medicine, and the investigation of exer-
cise dose–response on several clinical endpoints becomes
irrelevant, unless there are accurate metrics in place to quan-
tify the actual dosage undertaken by the patient. Combining
ExRDI with appropriate reporting of intervention characteris-
tics will allow for more accurate description of the dose of ex-
ercise prescribed and tolerability of that dose. Subsequently,
this will allow for greater insight into the tolerability of exer-
cise, ability to better compare exercise dose across different
populations and provide a more specific framework for exer-
cise prescription and modification.
RT prescription is complex, with many variables that
can be manipulated (exercises, sets, repetitions, load, rest pe-
riod, time under tension, etc.). Consequently, there is unlikely
to be a consensus on a gold-standard method to quantify RT
load, and choice of method will be a combination of popu-
lation studied, reason for use, and feasibility. For example,
methods to quantify volume from machine, dumbbell or
free weights are likely to be different than those from plyo-
metric exercises or resistance bands and should be tracked
separately. Additionally, calculating volume load with
group-based circuit training or home training may be difficult
and impractical. Additionally, tracking relative volume (i.e.,
sets  repetitions  percentage of one-repetition maximum)
as opposed to absolute (sets  repetitions  load) would add a
greater degree of accuracy in accounting for individual strength
levels and offering further insight into themagnitude of progres-
sion. Nevertheless, we contend that the calculation of volume
load is a simple and quick method that can allow for better
monitoring, adjusting, and reporting of the RT prescription (25).
It is important to note that traditional metrics, such as atten-
dance and loss-to follow up, are not without value. For example,
from a behavioral perspective, regular attendance at exercise
sessions/programs may demonstrate that an individual has de-
veloped the self-regulatory skills to set a goal of participating
in an exercise session and translated that intention/goal into ac-
tion by enacting a plan and overcoming barriers that could have
impeded attendance (26–31). Consequently, attendance and loss
TABLE 3. Reasons for dose modifications.
Variable/Reasons No. Patientsa Pct. No. Sessions Pct.
Permanent discontinuation 4 9 65 4
Health-related
Increased bone pain 2 5 23 2
Health deterioration 1 3 28 2
Fall at home 1 3 14 1
Exercise interruptionb 24 51 154 9
Health-related
General illness 6 13 25 1
Treatment-related pain 2 4 17 1
Conflicting appointments 4 9 9 1
Fatigue 1 2 3 0
Nausea 2 4 4 0
Non–health-related
Vacation 15 32 96 9
Missing sessionsb 41 87 135 8
Health-related
Conflicting appointments 31 66 79 5
General illness 16 34 16 1
Fatigue 4 9 5 0
Nausea 3 6 3 0
Treatment-related pain 1 2 1 0
Upper-extremity pain 1 2 2 0
Non–health-related
Other 10 21 15 1
Vacation 3 6 4 0
No reason 1 2 1 0
Dose modificationsb 40 85 149 9
Health-related
Fatigue 16 34 29 2
Lower extremity pain 11 23 43 2
Upper extremity pain 11 23 15 1
Bone pain 3 6 5 0
Nausea 2 4 2 0
Non health-related
Otherc 28 60 47 3
Not recorded 6 13 6 0
Time constraints 2 4 2 0
Dose escalation 19 40 30 2
Definitions: permanent discontinuation: permanent discontinuation of exercise prior to week
12; exercise interruption: missing ≥3 consecutive supervised sessions; missing sessions:
missing single or 2 consecutive sessions; dose modification: ≥1 session required dose
modification, and the total number of sessions requiring a dose reduction; dose escalation:
any session where dose was modified to progress individuals (i.e., load was higher than ini-
tially prescribed.
aAll metrics are collectively counted as one entity in the same patient unless otherwise
indicated.
bNumber of reasons for dose modification sums to greater than the total number of patients
listed since several patients required dose modification for different reasons.
cOther: time constraints, equipment availability, previously missed session.
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to follow-up (i.e., retention) may offer value and insight into the
efficacy of an intervention aimed at behavior change. Ulti-
mately, combining these metrics will allow for an expansion
of attendance and provide both breadth and specificity in future
interventions evaluating elements of an exercise intervention,
such as adherence, dose, and tolerance.
Notably, the proposed metrics may also be applied to other
populations where the exercise dose might require modifica-
tions to accommodate comorbidities or conditions (e.g. chronic
obstructive pulmonary disease, knee osteoarthritis or diabetes).
We have included a master template (see Supplemental Digital
Content 1, master template for calculating RT dose metrics,
http://links.lww.com/MSS/B719) that can be adapted to other
RT interventions to assist researchers/practitioners looking to
adopt these metrics. In summary, previously described methods
for reporting aerobic exercise interventions in cancer can be
adapted to provide valuable information on the tolerability and
adherence to RT in exercise interventions for cancer patients.
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